Maquet nabs FDA approval, CE mark for aortic graft

Justine Varieur Cadet | | Health Imaging | Screening
Maquet Cardiovascular has received FDA 510(k) clearance, as well as European CE mark approval, to market its Cardioroot aortic graft, a one-piece design, aortic root graft.

The Wayne, N.J.-based company said its Cardioroot will be used by vascular and cardiovascular surgeons to surgically repair or replace diseased and damaged aortas. It is expected to be commercially available in the EU within the next 60 days.

The graft design of mimics the anatomy of the patient's aortic root, including the natural sinuses of valsalva, which supply blood to the heart's own arteries. Cardioroot's shape allows sewing of valve remnants or a prosthetic valve within the tube, Maquet said.

Cardioroot is now commercially available in the U.S., according to the company, and is expected to be commercially available in the EU within the next 60 days.

Justine Varieur Cadet

Related Content

Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.